Jasper Therapeutics Is Maintained at Market Outperform by JMP Securities

Dow JonesJan 6 08:40 ET · Ratings

Jasper Therapeutics to Host Virtual Webinar Presenting Preliminary Data From BEACON Study of Briquilimab for Chronic Spontaneous Urticaria

Quiver QuantitativeJan 6 08:14 ET

Jasper Therapeutics to Host Webinar to Present Preliminary Data From the BEACON Study of Briquilimab in Chronic Spontaneous Urticaria on January 8, 2025

GlobeNewswireJan 6 08:00 ET

JMP Securities Maintains Jasper Therapeutics(JSPR.US) With Buy Rating, Maintains Target Price $70

Moomoo NewsJan 6 03:32 ET · Ratings

3 Best Stocks to Buy Now, 1/3/2025, According to Top Analysts

TipRanksJan 3 01:52 ET · Ratings

Analysts Are Bullish on These Healthcare Stocks: Jasper Therapeutics (JSPR), Celldex (CLDX)

TipRanksJan 2 07:40 ET · Ratings